An early-stage biotechnology company builder and investor, Lauren combines her serious science and business chops to develop therapeutics that focus on significant unmet patient needs. As CEO of Counterakt Therapeutics, Mifflin is leading the development of novel small molecule therapeutics for pediatric neurological diseases. Her doctoral work at Harvard University exploring new targets for amyotrophic lateral sclerosis (ALS) treatment helped to advance RIPK1 inhibitors into Phase 2 clinical trials by Denali Therapeutics and Sanofi.

Lauren has previously raised tens of millions for numerous biotech companies across her company building roles at 5AM Ventures, drug discovery organization Alloy Therapeutics, and Frazier Life Sciences, while shepherding start-ups through critical early development phases. Since losing her aunt to ALS, Lauren has dedicated her time to promote research into treatments for neurodegenerative diseases as a reviewer for the ALS Association and Michael J. Fox Foundation.